Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

BLPH stock opened at $0.04 on Friday. Bellerophon Therapeutics has a 52 week low of $0.03 and a 52 week high of $0.10. The company has a market capitalization of $452,510.00, a price-to-earnings ratio of -0.04 and a beta of 0.71. The firm’s 50-day moving average is $0.04 and its two-hundred day moving average is $0.05.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.